Spots Global Cancer Trial Database for Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

Official Title: Evaluation of the Effect of Ocoxin-Viusid® Nutritional Supplement in the Life Quality in Patients Diagnosed With Advanced Pancreatic Adenocarcinoma. Phase II

Study ID: NCT03717298

Conditions

Adenocarcinoma of the Pancreas

Pancreatic Cancer

Advanced Cancer

Digestive System Neoplasms

Pancreatic Neoplasms

Endocrine Gland Neoplasms

Digestive System Diseases

Endocrine System Diseases

Pancreatic Diseases

Interventions

Ocoxin-Viusid®

Study Description

Brief Summary: The investigators hypothesized that with the administration of the nutritional supplement Ocoxin-Viusid® is expected to improve the quality of life and enhance tolerance to chemotherapy in at least 70% of patients diagnosed with advanced pancreatic adenocarcinoma, treated at the "Hermanos Ameijeiras" Surgical Clinical Hospital. Phase II clinical trial, open, multicenter, nonrandomized.

Detailed Description: To assess the effect of Ocoxin-Viusid® on the quality of life of patients with advanced pancreatic adenocarcinoma. To evaluate the effect of Ocoxin-Viusid® on the quality of life of patients. To evaluate the influence of Ocoxin-Viusid® on tolerance to onco-specific therapy. Identify the changes that occur in the nutritional status of patients receiving the supplement. To evaluate the toxicity of Ocoxin-Viusid® in combination with chemotherapy in patients with advanced pancreatic adenocarcinoma.